Search results
Results from the WOW.Com Content Network
Progressive disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Evaluation of non-target lesions. Complete response (CR): Disappearance of all non-target lesions and normalization of tumor marker level
No new suspicious 18F-FDG avid lesions. If progression by RECIST must verify with follow up; Partial metabolic response (PMR) Reduction of a minimum of 30% in target measurable tumor 18F-FDG SUL peak, with absolute drop in SUL of at least 0.8 SUL units. No increase >30% of SUL or size in all other lesions; No new lesions; Stable metabolic ...
Immuno-oncology, part of the broader field of cancer immunotherapy, involves agents which harness the body's own immune system to fight cancer. Traditionally, patient responses to new cancer treatments have been evaluated using two sets of criteria, the WHO criteria and the response evaluation criteria in solid tumors (RECIST).
Another form of targeted therapy involves the use of nanoengineered enzymes to bind to a tumor cell such that the body's natural cell degradation process can digest the cell, effectively eliminating it from the body. Targeted cancer therapies are expected to be more effective than older forms of treatments and less harmful to normal cells.
A myeloid sarcoma (chloroma, granulocytic sarcoma, [1]: 744 extramedullary myeloid tumor) is a solid tumor composed of immature white blood cells [2] called myeloblasts. A chloroma is an extramedullary manifestation of acute myeloid leukemia ; in other words, it is a solid collection of leukemic cells occurring outside of the bone marrow .
The TNM Classification of Malignant Tumors (TNM) is a globally recognised standard for classifying the anatomical extent of the spread of malignant tumours (cancer). It has gained wide international acceptance for many solid tumor cancers, but is not applicable to leukaemia or tumors of the central nervous system. Most common tumors have their ...
While uncommon in solid tumors, chromosomal translocations are a common cause of these diseases. This commonly leads to a different approach in diagnosis and treatment of hematological malignancies. Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology.
They may appear as either non-caseating or solidly caseating lesions. [20] Initially, tuberculomas appear hypodense on computed tomography (CT) scans with significant surrounding edema. [23] [3] The "target sign" is pathognomonic for tuberculoma on CT, with a nodular ring-enhancing mass and central calcification.